Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

被引：108

作者：

Rustin, GJS ^{[1
]}

Bast, RC

Kelloff, GJ

Barrett, JC

Carter, SK

Nisen, PD

Sigman, CC

Parkinson, DR

Ruddon, RW

机构：

[1] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood HA6 2RN, Middx, England

[2] Univ Texas, MD Anderson Canc Ctr, Dept Translat Res, Houston, TX 77030 USA

[3] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

[4] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[5] Abbott Labs, Global Oncol Dev, Abbott Pk, IL 60064 USA

[6] CCS Associates, Mountain View, CA USA

[7] Amgen Inc, Thousand Oaks, CA 91320 USA

[8] Johnson & Johnson Corp, New Brunswick, NJ USA

来源：

CLINICAL CANCER RESEARCH | 2004年 / 10卷 / 11期

关键词：

D O I：

10.1158/1078-0432.CCR-03-0787

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3919 / 3926

页数：8

共 84 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2]

[Anonymous], 2003, J Clin Oncol, DOI [10.1200/jco.2003.02.955, DOI 10.1200/JCO.2003.02.955, DOI 10.1200/JC0.2003.02.955, 10.1200/JCO.2003.02.955]

[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[4] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].

BAST, RC ;

KLUG, TL ;

STJOHN, E ;

JENISON, E ;

NILOFF, JM ;

LAZARUS, H ;

BERKOWITZ, RS ;

LEAVITT, T ;

GRIFFITHS, CT ;

PARKER, L ;

ZURAWSKI, VR ;

KNAPP, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887

[5] REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].

BAST, RC ;

FEENEY, M ;

LAZARUS, H ;

NADLER, LM ;

COLVIN, RB ;

KNAPP, RC .

JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337

[6] CA 125: The past and the future [J].

Bast, RC ;

Xu, FJ ;

Yu, YH ;

Barnhill, S ;

Zhang, Z ;

Mills, GB .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187

[7]

Bast Robert C Jr, 2002, Cancer Treat Res, V107, P61

[8]

Brewer MA, 2003, CLIN CANCER RES, V9, P20

[9] Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel [J].

Bridgewater, JA ;

Nelstrop, AE ;

Rustin, GJS ;

Gore, ME ;

McGuire, WP ;

Hoskins, WJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :501-508

[10] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

← 1 2 3 4 5 6 7 8 9 →